Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2025-01-23 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
2024年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is titled as an "Annual Performance Forecast Announcement" for the fiscal year 2024, providing preliminary financial data such as net profit estimates and explanations for major changes. It explicitly states that the data are unaudited and preliminary, with final audited figures to be disclosed in the 2024 Annual Report. The document is short (under 5,000 characters) and serves as a forecast or earnings preview rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is an announcement of expected financial results, which aligns with the definition of an Earnings Release (ER) as an initial announcement of quarterly/periodical financial results with key highlights only. FY 2024
2025-01-23 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled as the "2024 Third Quarter Report" of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and explanations of significant changes in financial data. The report covers the period ending September 30, 2024, and includes comparative data from previous periods. It explicitly states that the quarterly report is unaudited and includes management's responsibility statements. The content is comprehensive and includes financial metrics, shareholder information, major events, and detailed notes on financial performance and risks. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is IR (Interim / Quarterly Report). 9M 2024
2024-10-28 Chinese
第五届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board regarding the approval of the company's 2024 third quarter report. It references the actual quarterly report being published separately on the stock exchange website with a specific announcement number. The document itself does not contain the financial data or substantive analysis of the quarterly report but only the resolution approving it. The document length is short (955 characters) and serves as an announcement of the meeting decision rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to the quarterly report but not the report itself.
2024-10-28 Chinese
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth board of directors' third meeting of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendance, and the approval of the 2024 third quarter report. The document references the actual third quarter report published separately on the Beijing Stock Exchange website, indicating this document is not the report itself but an announcement of the board meeting decisions related to the report. The document length is short (1041 characters), and it serves as a meeting resolution announcement rather than containing substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and decisions.
2024-10-28 Chinese
关于完成法人变更并换领营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a legal representative change and the reissuance of the business license for Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the election of a new chairman who becomes the legal representative and the completion of the corresponding business registration update. There is no financial data, no report or presentation attached, and the document is relatively short (857 characters). It is a regulatory announcement about corporate governance changes but not a formal management or board change announcement focused on personnel changes alone. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like MANG (which is for board or senior management changes announcements) because this is more about legal representative and business license update, a regulatory compliance matter.
2024-09-08 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as assets, liabilities, net profit, earnings per share, and other financial metrics for the half-year period. It also includes comprehensive information about the company's business operations, shareholder structure, changes in controlling shareholders, and significant events during the reporting period. The length of the document (over 10,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.